AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome

by adminTorusBrand | Jul 20, 2017 | Axim Biotechnologies, Press Releases

AXIM Biotechnologies, Inc. (AXIM Biotech) AXIM, +2.42% a world leader in cannabinoid research and development, today announced that it has entered into a Services Agreement with an Israel-based contract research organization (CRO) to begin a clinical proof of concept...

Reuters Features Medical Marijuana, Inc.’s Major Investment Company AXIM Biotech In Article Citing Company’s Development Of Marijuana-Based Painkiller To Combat Opioid Crisis

by adminTorusBrand | Jun 27, 2017 | Axim Biotechnologies, Press Releases

NEW YORK, June 27, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM), a world leader in...

Medical Marijuana, Inc. Major Investment AXIM Biotech Files Patent On Controlled Release Chewing Gum To Provide Opioid Addiction Treatment

by adminTorusBrand | Jun 26, 2017 | Axim Biotechnologies, Press Releases

NEW YORK, June 26, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC QB:AXIM), a world leader in...

AXIM® Biotechnologies Seeks Patent to Treat Opioid Addiction

by adminTorusBrand | Jun 23, 2017 | Axim Biotechnologies, Company News

[vc_row][vc_column][vc_column_text]The newly filed patent involves a novel chewing gum composition developed for the controlled release of cannabinoids and opioid agonists and/or antagonists for treatment of addiction and dependance. The chewing gum also has potential...

AXIM® Biotechnologies Clears Another Hurdle in Development of Multiple Sclerosis Treatment

by adminTorusBrand | May 4, 2017 | Axim Biotechnologies, Company News

AXIM® Biotechnologies is moving forward with the development of MedChew Rx® pharmaceutical chewing gum products, which are intended as a treatment of multiple sclerosis (MS) symptoms. The company’s product development partner Quay Pharmaceuticals Ltd. has obtained the...

Medical Marijuana, Inc. Major Investment AXIM Biotech Moves Forward With Development Of MedChew Rx Pharmaceutical Chewing Gum

by adminTorusBrand | May 3, 2017 | Axim Biotechnologies, Press Releases

SAN DIEGO, May 3, 2017 — Medical Marijuana, Inc. (MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc.’s (AXIM® Biotech) (AXIM) product development...